Paul R Kirchgraber Laboratory Corp Of America Holdings (LH) insider trading activity

Paul R Kirchgraber is CEO, Covance Drug Development of LABORATORY CORP OF AMERICA HOLDINGS. Currently has a direct ownership of 12,946 shares of LH, which is worth approximately $2.96 Million. The most recent transaction as insider was on May 19, 2023, when has been sold 4,300 shares (Common Stock) at a price of $216.91 per share, resulting in proceeds of $932,713. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 12.9K

0% 3M change

0% 12M change

Total Value Held $2.96 Million

Paul R Kirchgraber Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
May 19 2023	SELL Open market or private sale	$932,713 $216.91 p/Share	4,300 Reduced 24.93%	12,946 Common Stock
May 19 2023	BUY Exercise of conversion of derivative security	$784,793 $182.51 p/Share	4,300 Added 19.96%	17,246 Common Stock
Mar 30 2023	SELL Payment of exercise price or tax liability	$648,484 $224.7 p/Share	2,886 Reduced 18.23%	12,946 Common Stock
Mar 30 2023	BUY Grant, award, or other acquisition	-	6,763 Added 29.93%	15,832 Common Stock
Feb 21 2023	SELL Open market or private sale	$2,004,640 $250.58 p/Share	8,000 Reduced 46.87%	9,069 Common Stock
Feb 21 2023	BUY Exercise of conversion of derivative security	$547,530 $182.51 p/Share	3,000 Added 14.95%	17,069 Common Stock
Feb 13 2023	SELL Payment of exercise price or tax liability	$35,234 $248.13 p/Share	142 Reduced 1.0%	14,069 Common Stock
Feb 11 2023	BUY Exercise of conversion of derivative security	-	483 Added 3.29%	14,211 Common Stock
Feb 06 2023	SELL Payment of exercise price or tax liability	$40,098 $244.5 p/Share	164 Reduced 1.18%	13,728 Common Stock
Feb 04 2023	BUY Exercise of conversion of derivative security	-	560 Added 3.87%	13,892 Common Stock
Feb 02 2023	SELL Payment of exercise price or tax liability	$35,953 $254.99 p/Share	141 Reduced 1.05%	13,332 Common Stock
Feb 02 2023	BUY Exercise of conversion of derivative security	-	443 Added 3.18%	13,473 Common Stock
Nov 01 2022	SELL Payment of exercise price or tax liability	$198,523 $222.56 p/Share	892 Reduced 6.41%	13,030 Common Stock
Nov 01 2022	BUY Exercise of conversion of derivative security	-	2,007 Added 12.6%	13,922 Common Stock
Mar 28 2022	SELL Payment of exercise price or tax liability	$455,540 $276.42 p/Share	1,648 Reduced 12.15%	11,915 Common Stock
Mar 27 2022	BUY Grant, award, or other acquisition	-	3,707 Added 21.46%	13,563 Common Stock
Feb 14 2022	SELL Payment of exercise price or tax liability	$29,449 $272.68 p/Share	108 Reduced 1.08%	9,856 Common Stock
Feb 12 2022	BUY Exercise of conversion of derivative security	-	317 Added 3.08%	9,964 Common Stock
Feb 04 2022	SELL Payment of exercise price or tax liability	$45,784 $277.48 p/Share	165 Reduced 1.68%	9,647 Common Stock
Feb 04 2022	BUY Exercise of conversion of derivative security	-	560 Added 5.4%	9,812 Common Stock
Feb 02 2022	SELL Payment of exercise price or tax liability	$39,338 $273.18 p/Share	144 Reduced 1.53%	9,252 Common Stock
Feb 02 2022	BUY Exercise of conversion of derivative security	-	443 Added 4.5%	9,396 Common Stock
Nov 01 2021	SELL Payment of exercise price or tax liability	$259,324 $288.78 p/Share	898 Reduced 9.12%	8,953 Common Stock
Nov 01 2021	BUY Exercise of conversion of derivative security	-	2,007 Added 16.93%	9,851 Common Stock
May 06 2021	SELL Open market or private sale	$691,375 $276.55 p/Share	2,500 Reduced 24.17%	7,844 Common Stock

PRK

Paul R Kirchgraber

CEO, Covance Drug Development

Burlington, NC

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells LH shares.

Notify only if

Value

Insider Trading

Get notified when an Laboratory Corp Of America Holdings insider buys or sells LH shares.

Notify only if

Operation

Value

Type

News

Receive news related to LABORATORY CORP OF AMERICA HOLDINGS

Track Activities on LH

Account